We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+41.99%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$7.04B
AUM Growth
+$1.98B
Cap. Flow
-$1.2B
Cap. Flow %
-17.09%
Top 10 Hldgs %
79.89%
Holding
87
New
12
Increased
14
Reduced
15
Closed
5

Top Buys

Rank Stock Value
1
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$51.7M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$19.5M
3
DSCI
Derma Sciences, Inc. Common Stock (DE)
DSCI
+$16.6M
4
QCOR
QUESTCOR PHARMA INC
QCOR
+$13.7M
5
XOMA
Xoma
XOMA
+$12.5M

Top Sells

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$195M
2
VPHM
VIROPHARMA INC
VPHM
+$96M
3
CLVS
Clovis Oncology, Inc.
CLVS
+$15.8M
4
AEGR
Aegerion Pharmaceuticals
AEGR
+$8.82M
5
INFI
Infinity Pharmaceuticals, Inc.
INFI
+$8.22M

Sector Composition

Rank Sector Weight
1 Healthcare 48.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLVS
26
DELISTED
Clovis Oncology, Inc.
CLVS
$18.3M 0.26%
301,744
-223,369
-43% -$15.8M
ARWR icon
27
Arrowhead Research
ARWR
$12.3B
$17.9M 0.25%
+3,140,000
New +$12.1M
CHTP
28
DELISTED
CHELSEA THERAPEUTICS INT'L LTD
CHTP
$17.3M 0.25%
5,794,753
+1,018,966
+21% +$2.93M
INSM icon
29
Insmed
INSM
$27.5B
$14.8M 0.21%
945,803
+150,000
+19% +$1.91M
KYTH
30
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
$12.1M 0.17%
265,000
+100,000
+61% +$2.99M
SGYP
31
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$11.9M 0.17%
2,644,787
– –
AMBI
32
DELISTED
Ambit Biosciences Corp
AMBI
$11.6M 0.16%
747,962
– –
GYRE icon
33
Gyre Therapeutics
GYRE
$733M
$11M 0.16%
+2,626
New +$10.6M
INFI
34
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$10.2M 0.15%
586,936
-429,497
-42% -$8.22M
ACGN
35
DELISTED
Aceragen Inc
ACGN
$10.2M 0.15%
43,168
+10,047
+30% +$2.01M
ARRY
36
DELISTED
Array Biopharma Inc
ARRY
$9.33M 0.13%
1,500,000
– –
ANAC
37
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$9.31M 0.13%
876,463
– –
IONS icon
38
Ionis Pharmaceuticals
IONS
$9.93B
$9.27M 0.13%
247,036
– –
MTEM
39
DELISTED
Molecular Templates, Inc.
MTEM
$8.61M 0.12%
11,227
+1,560
+16% +$1.28M
PTLA
40
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$8.02M 0.11%
299,911
-100,003
-25% -$2.38M
PRTA icon
41
Prothena Corp
PRTA
$485M
$7.48M 0.11%
369,650
– –
QLTI
42
DELISTED
QLT Inc
QLTI
$7.11M 0.1%
1,535,863
– –
OSIR
43
DELISTED
Osiris Therapeutics, Inc. Common Stock
OSIR
$6.25M 0.09%
+375,282
New +$5.55M
OMER icon
44
Omeros
OMER
$1.39B
$5.93M 0.08%
+608,404
New +$3.63M
XNPT
45
DELISTED
XENOPORT, INC.
XNPT
$5.87M 0.08%
1,034,112
– –
AGIO icon
46
Agios Pharmaceuticals
AGIO
$1.98B
$5.59M 0.08%
+200,000
New +$5.52M
IRWD icon
47
Ironwood Pharmaceuticals
IRWD
$709M
$5.46M 0.08%
550,625
-550,434
-50% -$5.4M
NVAX icon
48
Novavax
NVAX
$1.47B
$5.41M 0.08%
+85,846
New +$4.83M
PBYI icon
49
Puma Biotechnology
PBYI
$477M
$5.37M 0.08%
100,000
+16,667
+20% +$898K
BDSI
50
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$4.59M 0.07%
846,005
-54,500
-6% -$262K
1
2
3 4

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q3 2013 Portfolio in Review

As of Q3 2013, Julian Baker held 87 positions worth $7.04B, up 39% from $5.06B the previous quarter. Its ten largest holdings account for 80% of the portfolio.

Julian Baker withdrew a net $1.2B in Q3 2013, closing 5 positions and reducing 15 holdings. Its most notable exit was Arqule Inc, an estimated $2.04M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 48% of assets, up from 48% a quarter earlier.

Against the trend, Julian Baker opened a new position in Mirati Therapeutics, Inc. Common Stock worth $30M.

  • Julian Baker's largest Q3 2013 buy was Mirati Therapeutics, Inc. Common Stock: 1,980,074 shares worth $30M.
  • Julian Baker added most to SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q3 2013, an estimated $51.7M increase.
  • Julian Baker's biggest Q3 2013 reduction was PHARMACYCLICS INC, cutting an estimated $195M.
  • Julian Baker fully exited Arqule Inc in Q3 2013, selling an estimated $2.04M.
  • Julian Baker's ten largest holdings make up 80% of its $7.04B portfolio in Q3 2013.
  • Julian Baker opened 12 new positions and closed 5 in Q3 2013.
  • Julian Baker's portfolio value rose 39% quarter-over-quarter to $7.04B.

Based on Baker Bros. Advisors's 13F filing for Q3 2013, filed 14 Nov 2013.